EXPRESS MAIL NO: EL615232339US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Steven G. Reed et al.

Filed

September 20, 2000

For

COMPOSITIONS AND METHODS FOR THE THERAPY AND

DIAGNOSIS OF LUNG CANCER

Docket No.

: 210121.475C7

Box Patent Application Assistant Commissioner for Patents Washington, D.C. 20231

RECEIVED

JUL 3 1 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

David W. Parker

Registration No. 37,414

RECEIVED

SEP 1 3 2002

OFFICE OF PETITIONS

JEP:mls Enclosures:

Form PTO-1449
Cited References (11)
701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092 Phone: (206) 622-4900 Fax: (206) 682-6031

Wpn/210121 - Corixa/475c7/Ids/475c7.sta.doc



FORM PTŐ-1449 (REV.7-80)	9		S. DEPARTMENT		ATTY. DOCKET NO.	l l	XPRESS MAIL NO.				
(REV.7-80) PATENT AND TRADEMARK OFFICE					210121.475C7 EL615232339US						
INFO	ORM.	ATION DISCLOSU	RE STATEM	ENT	APPLICANTS Steven G. Reed et al.						
(Use several sheets if necessary)					FILING DATE	ROUP ART UNIT	345 345				
ب					September 20, 2000		**************************************				
U.S. PATENT DOCUMENTS											
*EXAMINER INITIAL		DOCUMENT NUMBER	OCUMENT NUMBER DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
	AA										
DOCUMENT DATE COUNTRY RECEIVED SUBCLASS TRANSLATION YES NO											
		DOCUMENT NUMBER	DATE		COUNTRY RECE	VEI	SUBCLASS	TRANSLATION			
					JUL 3 1	20.2	<i>)</i>	YES NO			
	AB	WO 99/38973	08/05/99	WIPO	TECH CENTED	<i>2003</i>					
	AC	WO 96/02552	02/01/96	WIPO		100/2900)				
		ОТНІ	ER PRIOR A	RT (Including	Author, Title, Date, Pertinent Pa	ges, Etc.)					
	AD	Chen et al., '	Isolation an	d characteri	zation of a novel gene	express	ed in multipl	e cancers,"			
	^	Oncogene, 1	<i>2</i> :741-751, I	February 15	, 1996.						
	AE	· ·	El-Deiry W., "Role of oncogenes in resistance and killing by cancer therapeutic agents," Current Opinion in Oncology 9(1):79-87, January 1997.								
		_	3, () 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,								
	AF	i	Fenwick et al., "A subclass of Ras proteins that regulate the degradation of IkB," Science,								
		287:869-873	287:869-873, February 4, 2000.								
	AG	Gure et al., "Human lung cancer antigens recognized by autologous antibodies: definition									
		a novel cDN	A derived fr	om the tum	or suppressor gene loc	us on ch	romosome 3	p21.3,"			
		Cancer Rese				7	. T				
	АН		•	•	s of inflammatory dise		•	ng cDNA			
		microarrays,	Proc. Nati	. Acaa. Sci.	USA 94:2150-2155, M	larch 19	197.				
	Al										
	cell carcinoma: evidence of persistent oxidative stress in cancer," International Journal										
			Cancer 65(4):437-441, February 8, 1996.								
	AJ		Porter et al., "Mechanistic studies of the inhibition of MutT dGTPase by the carcinogenic metal Ni(II)," Chem. Res. Toxicol. 9(8):1375-1381, December 1996.								
EXAMINE	ER				DATE CONSIDERED						
* EXAMIN	EŘ· 1	nitial if reference consider	red whether or no	at criteria is in co	nformance with MPEP 600 Description	w line throu	igh citation if not in	,			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next comparison of the conformance and not considered.											

SEP 1 3 2002

And the second s			S. DEPARTMENT TENT AND TRAD		ATTY. DOCKET NO. 210121.475C7		EXPRESS MAIL NO. EL615232339US						
INFORMATION DISCLOSURE STATEMENT					APPLICANTS Steven G. Reed et al.								
(Use several sheets if necessary)					FILING DATE GROUP ART UNIT September 20, 2000								
			U.S.	. PATENT 1	DOCUMENTS		L						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLA	SS	SUBCLASS	FILING DATE IF APPROPRIATE				
	ВА												
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER	DATE		COUNTRY	CLA	.SS	SUBCLASS	TRANSLATION				
	BB				**		-		YES	NO			
	ВС						-						
	<u> </u>	OTHE	R PRIOR A	RT (Including	Author Title Date Porting	1 Danie 54				L			
	ВЕ	Schena et al., of 1000 genes	OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Schena et al., "Parallel human genome analysis: microarray-based expression monitoring of 1000 genes," Proc. Natl. Acad. Sci. USA 93:10614-10619, October 1996.										
	BF	hMTH1, in he	Wu et al., "Polymorphisms and probable lack of mutation in a human <i>mutT</i> homolog, <i>hMTH1</i> , in hereditary nonpoliposis colorectal cancer," <i>Biochemical and Biophysical Research Communications 214</i> (3): 1239-1245, September 25, 1995.										
	BG												
	вн												
	ВІ			120.20									
	ВЈ				7								
	вк												
EXAMINER				DATE CONSIDERED									
* EXAMINE		nitial if reference considere	ed, whether or not	criteria is in con	formance with MPEP 609. D	raw line thro	ough ci	itation if not in	<u>.</u>				